Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab.

ABSTRACT: Denosumab treatment is effective for the prevention of skeletal-related events in patients with bone metastases. However, hypocalcemia has been recognized as a serious adverse effect of denosumab. This study aimed to identify the risk factors for hypocalcemia in patients with bone metastases. In this prospective open-label study, 35 patients with bone metastases to be treated with denosumab were recruited. During the 3 months follow-up, 9 patients (25.7%) experienced hypocalcemia. Higher bone turnover status at baseline was observed in patients with hypocalcemia than in those without hypocalcemia following denosumab administration (total-P1NP, TRACP-5b, and S-NTX: all p < .05). Negative correlations were observed between the lowest calcium levels and baseline bone turnover markers (

SUBMITTER: Tsuchiya K 

PROVIDER: S-EPMC11911062 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature